期刊文献+

异基因造血干细胞移植术后移植物抗宿主病的研究进展 被引量:4

下载PDF
导出
摘要 造血干细胞移植(HSCT)特别是异基因造血干细胞移植(allo—HSCT)越来越多地用于治疗恶性血液系统疾病,而移植后出现的移植物抗宿主病(GVHD)是allo-HSCT的主要并发症和死亡原因之一。移植物抗宿主病按发生时间分为急性移植物抗宿主病(aGVHD)和慢性移植物抗宿主病(cGVHD)。
出处 《临床内科杂志》 CAS 2011年第11期725-728,共4页 Journal of Clinical Internal Medicine
基金 卫生行业科研专项公益基金项目(No.200802027)
  • 相关文献

参考文献7

二级参考文献67

  • 1许兰平,黄晓军,刘开彦,陈欢,刘代红,张耀臣,陈育红,韩伟,高志勇,陆道培.异基因造血干细胞移植治疗Ph^+急性淋巴细胞白血病[J].北京大学学报(医学版),2005,37(3):231-235. 被引量:13
  • 2许兰平,郭乃榄,郑缓,卢锡京,史琪,吴彤,范蕴明,张捷,黄晓军,张耀臣,江滨,陆道培.异基因骨髓移植的预处理相关毒性[J].中华血液学杂志,1994,15(10):511-513. 被引量:8
  • 3王科,石炳毅,钱叶勇,王晓雄.肾移植术后环孢素A肝毒性防治回顾性分析[J].解放军医学杂志,2006,31(6):614-615. 被引量:1
  • 4刘启发,范志平,孙竞,易正山,徐丹,张钰,魏永强,叶昌雄,杨凯,孟凡义.两种方案预防无血缘关系供者造血干细胞移植后移植物抗宿主病的效果比较[J].中华血液学杂志,2006,27(8):550-552. 被引量:4
  • 5Willenbacher W, Basara N, Blau IW, et al. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol, 2001, 112:820-823.
  • 6Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tat:an antibody that binds to the interleukin-2 receptor. Blood, 1994, 84 : 1320-1327.
  • 7Przepiorka D, Keman NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood, 2000, 95:83- 89.
  • 8Perales MA, Ishill N, Eomazow WA, et al. Long-term follow-up of patients treated with daclizumab for steroid-refractoryacute graft- vs-host disease. Bone Marrow Transplant,2007,40:481-486.
  • 9Bordigoni P, Dimicoli S, Clement L, et al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol, 2006,135:382-385.
  • 10Schmidt-Hieber M, Fietz T, Knauf W, et al. Efficacy of the interleukino2 receptor antagonist basiliximab insteroid-refractory acute graft-versus-host disease. Br J Haematol, 2005, 130: 568- 574.

共引文献55

同被引文献31

  • 1黄晓军,韩伟,许兰平,陈育红,刘代红,路谨,陈欢,张耀臣,江倩,刘开彦,陆道培.A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease[J].Chinese Medical Journal,2004,17(12):1778-1785. 被引量:27
  • 2赵璐,郑敏.移植物抗宿主病的皮肤表现及治疗进展[J].国际皮肤性病学杂志,2006,32(3):153-155. 被引量:4
  • 3Guo M, Hu KX, Yu CL, et al. Infusion of HLA-mismatched peripheralblood stem ceils improves the outcome of chemotherapy for acute mye-loid leukemia in elderly patients. Blood,2011,117:936-941.
  • 4Lv M,Huang XJ. Allogeneic hematopoietic stem cell transplantation inChina: where we are and where to go. J Hematol Oncol,2012,5 :10.
  • 5Li HW,Sykes M. Emerging concepts in haematopoietic cell transplanta-tion. Nat Rev Immunol,2012,12-403-416.
  • 6Mackinnon S, Chakraverty R. Families get mobilized to treat AML.Blood,2011,117:746-748.
  • 7Hymes SR, Tumer ML, Champlin RE, et al. Cutaneous manifestations of chronic graftversushost disease [ J 1. Biol Blood Marrow Transplant, 2006, 12( :[1 ) :1101-1103.
  • 8Sanli H, Arat M, Oskay T, et al. Evaluation of nail involvement in pa- tients with chronic cutaneous graft versus host disease: a single-center study from Turkey[J] Int J Dermatol, 2004, 43(3) :176-180.
  • 9Palencia SI, Rodriguez-Peraho JL, Castao E,et al. Lichenoid nail chan- ges as sole external manifestation of graftvs host disease[ J]. Int J Derma- tol, 2002,41 ( 1 ) :44-45.
  • 10Wu PA, Cowen EW. Cutaneous graft-versus-host disease clinical considera- tions and management [ J 3. Curr Probl Dermato1,2012,43 (12) : 101-115.

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部